![](https://cdn.sanity.io/images/0vv8moc6/onclive/8fd2e368235d656b16efa59765b4cf63df21604d-262x145.jpg?fit=crop&auto=format)
Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL
Moritz Fürstenau, MD, Division of Haematology, Immunology, Infectiology, Intensive Care, and Oncology, University of Cologne, discusses the safety profile of venetoclax (Venclexta) plus obinutuzumab (Gazyva) with or without ibrutinib (Imbruvica) vs …